17070-58-5

Basic information

• Product Name: 1-BENZOFURAN-2-SULFONYL CHLORIDE
• Synonyms: 1-BENZOFURAN-2-SULFONYL CHLORIDE;1-Benzofurane-2-sulfonylchloride;Benzofuran-2-sulfonyl chloride;Benzofuran-2-sulphonylchloride;1-Benzofuran-2-sulphonyl chloride;2-Benzofuransulfonyl chloride
• CAS NO: 17070-58-5
• Molecular Formula: C₈H₅ClO₃S
• Molecular Weight: 216.64
• Product Categories: Furan&Benzofuran
• Mol File: 17070-58-5.mol

Chemical Properties

• Melting Point: 78-80°C
• Boiling Point: 322.5 °C at 760 mmHg
• Flash Point: 148.8 °C
• Appearance: White to light yellow crystal powde
• Density: 1.514 g/cm³
• Vapor Pressure: 0.000524mmHg at 25°C
• Refractive Index: 1.623
• CAS DataBase Reference: 1-BENZOFURAN-2-SULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZOFURAN-2-SULFONYL CHLORIDE(17070-58-5)
• EPA Substance Registry System: 1-BENZOFURAN-2-SULFONYL CHLORIDE(17070-58-5)

Safety Data

• Hazard Codes: C,Xi
• Statements: 34-29-14-36
• Safety Statements: 26-36/37/39-45-30-22
• RIDADR: 3261
• Hazardous Substances Data: 17070-58-5(Hazardous Substances Data)

Usage

Chemical Properties

white to light yellow crystal powde

InChI:InChI=1/C8H5ClO3S/c9-13(10,11)8-5-6-3-1-2-4-7(6)12-8/h1-5H

Upstream product

• 124043-83-0 lithium benzo[b]furan-2-sulfinate 
• 271-89-6 1-benzofurane 

Relevant articles and documents

Synthesis of Heteroaryl Sulfonamides from Organozinc Reagents and 2,4,6-Trichlorophenyl Chlorosulfate

A method for the preparation of aryl and heteroaryl sulfonamides using 2,4,6-trichlorophenyl chlorosulfate (TCPC) is described. The reaction of 2-pyridylzinc reagents with TCPC resulted in 2,4,6-trichlorophenyl (TCP) pyridine-2-sulfonates, and the parent pyridine-2-sulfonate was shown to react with amines. Less electron-rich aryl- and heteroarylzinc reagents reacted with TCPC to afford sulfonyl chlorides that were converted in situ to sulfonamides.

BISSULFONAMIDE COMPOUNDS AS AGONISTS OF GALR1, COMPOSITIONS, AND METHODS OF USE

Embodiments of the present invention provide bissulfonamide compounds that are agonists of GalR1. The present invention further provides compositions comprising bissulfonamide compounds that are agonists of GalR1, and methods of use of such compounds and compositions.

Acyl sulfonamide anti-proliferatives. Part 2: Activity of heterocyclic sulfonamide derivatives

The anti-proliferative activity of acylated heterocyclic sulfonamides is described in Vascular Endothelial Growth Factor-dependent Human Umbilical Vascular Endothelial Cells (VEGF-HUVEC) and in HCT116 tumor cells in a soft agar diffusion assay.

N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin

Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

Bispiperidines as antithrombotic agents

Novel compounds which are inhibitors of the binding of fibrinogen to the Gp IIb/IIIa platelet receptors, and which can be used therepeutically as antithrombotic agents

Hydantoin derivatives

The present invention relates to novel hydantoin derivatives, processes for producing said hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel intermediate compounds in the synthesis of said hydantoin derivatives. The present invention is based on the selection of a hydantoin which is bonded by a sulfonyl group to various substituents at the 1-position of the hydantoin skeleton. The compounds of the present invention have a strong inhibitory activity against aldose reductase. These compounds are extremely useful for the treatment and/or prevention of various forms of diabetic complications based on the accumulation of polyol metabolites.